References
- GradisharWTreatment challenges for community oncologists treating postmenopausal women with en-resistant, hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancerCancer Manag Res20168859427468248
- ChangJFanWEndocrine therapy resistance: current status, possible mechanisms and overcoming strategiesAnticancer Agents Med Chem201313346447522931419
- PiccartMHortobagyiGNCamponeMEverolimus plus exemestane for hormone-receptor-positive, human epidermal growth factor receptor-2-negative advanced breast cancer: overall survival results from BOLERO-2Ann Oncol201425122357236225231953
- TurnerNCRoJAndreFPalbociclib in hormone-receptor-positive advanced breast cancerN Engl J Med2015373320921926030518
- National Comprehensive Cancer Network [database on the Internet]Fort Washington PA: NCCN Guidelines for Breast Cancer: Endocrine Therapy for Stage IV or Recurrent Metastatic DiseaseMS-54-57 Available from: https://www.nccn.org/professionals/physician_gls/pdf/breast.pdfAccessed July 13, 2016
- KingKMLupichukSBaigLWebsterMBasiSWhyteDRixSOptimal use of taxanes in metastatic breast cancerCurr Oncol2009163820
- SachdevJCJahanzebMUse of cytotoxic chemotherapy in metastatic breast cancer: putting taxanes in perspectiveClin Breast Cancer20161621738126603443
- CortesJO’ShaughnessyJLoeschDEribulin monotherapy versus treatment of physicians choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomized studyLancet2011377976991492321376385
- SharmaPBiology and management of patients with triple-negative breast cancerOncologist20162191050106227401886
- RugoHSPritchardKIGnantMIncidence and time course of everolimus-related adverse events in postmenopausal women with hormone receptor-positive advanced breast cancer: insights from BOLERO-2Ann Oncol201425480881524615500
- TurnerNCHuang BartlettCCristofanilliMPalbociclib in hormone receptor-positive advanced breast cancerN Engl J Med20153731716721673
- CardosoFBedardPLWinerEPInternational guidelines for management of metastatic breast cancer: combination vs sequential single-agent chemotherapyJ Natl cancer Inst2009101171174118119657108
- FinnRSCrownJPLangIThe cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 studyLancet Oncol2015161253525524798